Galectin Therapeutics Inc. (GALT)

[1234jklm]

Huge news. The team that helped win the 2018 Nobel prize for cancer immunotherapy, and conducting the cancer IO trial in humans is now saying, in an upcoming conference, that GR-MD-02 improves overall cancer survival: "Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival."

This is very significant because researchers are traditionally extremely cautious about making any claims about a cancer drug improving overall survival unless the data is rock solid. Providence has new data coming up. Patients who respond to GR-MD-02 have the option to continue therapy, and apparently the results are very good!

http://www.keystonesymposia.org/index.cfm?e=Web.Meeting.Program&meetingid=1626&subTab=program